Le Lézard
Classified in: Health
Subject: SVY

Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2017


LONDON, Nov. 16, 2017 /PRNewswire/ -- Fore Pharma announced the results of its Renal Cell Carcinoma patients study in a new report 'Global Renal Cell Carcinoma Epidemiology and Patient Flow Analysis - 2017'.



Download the full report: https://www.reportbuyer.com/product/3895274



The report provides insights into Renal Cell Carcinoma epidemiology, Renal Cell Carcinoma diagnosed patients, and Renal Cell Carcinoma treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Renal Cell Carcinoma derived from epidemiological analysis, percentage of patients diagnosed with Renal Cell Carcinoma, and percentage of patients treated with a therapy.

The study helps executives estimate Renal Cell Carcinoma market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Renal Cell Carcinoma prevalence, Renal Cell Carcinoma diagnosis rate, and Renal Cell Carcinoma treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.

Key Features of the Report:
- Renal Cell Carcinoma Patient Flow
- Renal Cell Carcinoma Prevalence
- Renal Cell Carcinoma Diagnosed Patients
- Renal Cell Carcinoma Treated Patients

Download the full report: https://www.reportbuyer.com/product/3895274

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer


These press releases may also interest you

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...

at 03:05
Surge has just closed its second round of funding, raising ?7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov', as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé....

at 03:00
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who...



News published on and distributed by: